Globus Pallidus Pkan

Migration, Crosslink

📖

Globus Pallidus Pkan

active

wiki page Created: 2026-04-02T07:19:43 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-globus-pallidus-pkan

📖 Wiki Page

cell_type1997 wordssynced 2026-04-02

Introduction

Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, represents the most common form of neurodegeneration with brain iron accumulation (NBIA), accounting for approximately 50-70% of all NBIA cases. PKAN is an autosomal recessive disorder caused by mutations in the PANK2 gene, which encodes pantothenate kinase 2, a mitochondrial enzyme essential for the first and rate-limiting step in coenzyme A (CoA) biosynthesis. [@zhou2011]

The disease is characterized by progressive neurodegeneration with prominent iron deposition in the globus pallidus and substantia nigra pars reticulata (SNr), leading to a constellation of movement disorders including dystonia, dysarthria, rigidity, and Parkinsonism. The hallmark radiological finding is the "eye-of-the-tiger" sign on brain MRI, reflecting the unique pattern of iron deposition with central hyperintensity surrounded by hypointensity in the globus pallidus.

Globus pallidus neurons are particularly vulnerable in PKAN due to their high metabolic demands, unique iron-handling properties, and the critical role of CoA in their normal function. Understanding the molecular mechanisms underlying PKAN pathogenesis provides insights not only into this rare disorder but also into broader questions of iron metabolism, mitochondrial function, and neurodegeneration relevant to more common conditions like Parkinson's disease and Huntington's disease.

Overview

...

Introduction

Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, represents the most common form of neurodegeneration with brain iron accumulation (NBIA), accounting for approximately 50-70% of all NBIA cases. PKAN is an autosomal recessive disorder caused by mutations in the PANK2 gene, which encodes pantothenate kinase 2, a mitochondrial enzyme essential for the first and rate-limiting step in coenzyme A (CoA) biosynthesis. [@zhou2011]

The disease is characterized by progressive neurodegeneration with prominent iron deposition in the globus pallidus and substantia nigra pars reticulata (SNr), leading to a constellation of movement disorders including dystonia, dysarthria, rigidity, and Parkinsonism. The hallmark radiological finding is the "eye-of-the-tiger" sign on brain MRI, reflecting the unique pattern of iron deposition with central hyperintensity surrounded by hypointensity in the globus pallidus.

Globus pallidus neurons are particularly vulnerable in PKAN due to their high metabolic demands, unique iron-handling properties, and the critical role of CoA in their normal function. Understanding the molecular mechanisms underlying PKAN pathogenesis provides insights not only into this rare disorder but also into broader questions of iron metabolism, mitochondrial function, and neurodegeneration relevant to more common conditions like Parkinson's disease and Huntington's disease.

Overview

| Property | Value |
|----------|-------|
| Category | Neurodegeneration with Brain Iron Accumulation (NBIA) |
| Inheritance | Autosomal recessive |
| Gene | PANK2 (Pantothenate Kinase 2) |
| Chromosome | 20p12.3 |
| Protein | Mitochondrial pantothenate kinase |
| Enzyme Function | First step in CoA biosynthesis |
| Prevalence | 1-2 per million; ~50% of NBIA cases |
| Age of Onset | Childhood (typical), adulthood (atypical) |
| Primary Brain Regions | Globus pallidus (GPi/GPe), substantia nigra |

PANK2 Gene and Protein

Gene Structure

The PANK2 gene spans approximately 21 kb on chromosome 20p12.3 and contains 10 exons encoding a 512-amino acid protein. The protein localizes to the mitochondrial matrix, where it functions as a homodimer.

Enzyme Function

Pantothenate kinase (PanK) catalyzes the phosphorylation of vitamin B5 (pantothenate) to produce 4'-phosphopantothenate, the first and rate-limiting step in CoA biosynthesis:

Pantothenate + ATP → 4'-Phosphopantothenate + ADP

Four human pantothenate kinase isoforms exist (PANK1-4), with PANK2 being the mitochondrial isoform essential for CoA synthesis in tissues with high energy demands, including the brain.

Mutations

Over 150 pathogenic PANK2 mutations have been identified, including:

Missense mutations: Most common; often affect enzyme stability or activity
Nonsense mutations: Associated with severe phenotype
Splice site mutations: Often lead to truncated proteins
Frameshift mutations: Generally cause null alleles

Genotype-phenotype correlations exist, with some mutations associated with classical (early-onset) vs. atypical (late-onset) presentations. [@kristiansen2017]

Coenzyme A Metabolism

Central Role of CoA

Coenzyme A is a universal cofactor essential for:

Energy metabolism: CoA is required for the tricarboxylic acid (TCA) cycle, fatty acid oxidation, and ATP production
Biosynthetic pathways: Cholesterol, steroid hormones, and neurotransmitter synthesis
Protein modification: Post-translational acylation of proteins
Cellular signaling: Acyl-CoA species serve as signaling molecules

The brain has particularly high CoA requirements due to its high metabolic rate and complex lipid composition (CoA is essential for myelin formation).

CoA Homeostasis in Neurons

Neurons maintain CoA levels through:

De novo synthesis: PANK2-dependent pathway

Recycling: CoA is recycled from acyl-carnitine and pantetheine

Import: Limited pantothenate uptake across the blood-brain barrier

In PKAN, impaired PANK2 function leads to:

Decreased CoA synthesis
Accumulation of pantothenate
Secondary effects on mitochondrial function
Disruption of lipid metabolism

Pathogenic Mechanisms of CoA Deficiency

Multiple mechanisms link CoA deficiency to neurodegeneration: [@arber2020]

Mitochondrial dysfunction: Reduced CoA impairs TCA cycle function, reducing ATP production

Oxidative stress: Impaired mitochondrial function increases ROS production

Lipid dysregulation: Defects in myelin formation and neuronal membrane maintenance

Neurotransmitter synthesis: Acetyl-CoA is required for acetylcholine synthesis

Iron Metabolism in the Brain

Iron Homeostasis

The brain requires precise iron regulation:

Iron entry: Transferrin-bound iron enters via the blood-brain barrier
Cellular uptake: DMT1 (divalent metal transporter 1) and transferrin receptors
Storage: Ferritin in neurons and glia
Utilization: For mitochondrial function, neurotransmitter synthesis

Iron and Neurodegeneration

Excess iron is toxic through the Fenton reaction:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻

The hydroxyl radical (•OH) is highly reactive and damages proteins, lipids, and DNA.

Iron accumulation is observed in multiple neurodegenerative conditions: [@youdim2000]

Parkinson's disease: Substantia nigra
Huntington's disease: Striatum and cortex [@post1998]
Alzheimer's disease: Hippocampus and cortex
PKAN: Globus pallidus and substantia nigra

Why the Globus Pallidus?

The globus pallidus is particularly susceptible to iron accumulation due to:

High metabolic rate and mitochondrial density
Rich iron supply from the striatum
Lower ferritin expression than other brain regions
Unique iron-handling properties

Pathogenesis of PKAN

Primary Molecular Events

PANK2 mutation → Loss of pantothenate kinase activity

Reduced CoA synthesis → Cellular CoA deficiency

Mitochondrial dysfunction → Reduced ATP, increased ROS

Iron dysregulation → Enhanced iron uptake/retention

Neurodegeneration → Cell death in GP and SNr

Secondary Pathogenic Mechanisms

Oxidative Stress: CoA deficiency impairs mitochondrial respiration, increasing ROS production. Iron accumulation exacerbates oxidative stress through Fenton chemistry.

Lipid Dysregulation: CoA is essential for fatty acid metabolism and myelin synthesis. Disruption leads to membrane abnormalities and white matter changes.

Energy Failure: Reduced mitochondrial ATP production leads to neuronal dysfunction and death.

Excitotoxicity: Altered energy metabolism may impair glutamate transport, leading to excitotoxic damage.

Neuroinflammation: Reactive gliosis is observed in PKAN brains, potentially contributing to disease progression.

Role of Iron Accumulation

The relationship between CoA deficiency and iron accumulation remains an active area of investigation. Proposed mechanisms include: [@zhang2015]

Altered iron storage: CoA deficiency may affect ferritin function

Increased iron uptake: Upregulation of DMT1 and transferrin receptors

Impaired iron export: Reduced ferroportin function

Mitochondrial iron loading: Iron trapped in mitochondria due to impaired utilization

Clinical Features

Classical (Early-Onset) PKAN

Onset: Typically before age 6 years
Initial symptoms: Gait difficulty, dystonia (often focal)
Progression: Rapid, leading to wheelchair dependence within 10-15 years
Core features:
Progressive dystonia (generalized, axial > limb)
Dysarthria (spastic or hypokinetic)
Rigidity
Parkinsonism (bradykinesia, tremor)
Cognitive decline (variable)
Ocular abnormalities (retinitis pigmentosa, optic atrophy)

Atypical (Late-Onset) PKAN

Onset: Adolescence or adulthood (typically 10-30 years)
Initial symptoms: Speech difficulty, psychiatric features
Progression: Slower than classical form
Core features:
Dystonia (often focal,cranial)
Dysarthria (prominent)
Parkinsonism (prominent)
Less severe cognitive impairment

Natural History

The natural history of PKAN has been characterized through natural history studies: [@hogarth2013]

Early stage: Focal dystonia, mild gait disturbance
Middle stage: Generalized dystonia, speech involvement, cognitive changes
Late stage: Wheelchair dependence, severe motor impairment, complete dependency
Complications: Respiratory failure, infections, contractures

Rating Scales

The PKAN Rating Scale (PKAN-RS) has been developed to assess: [@hogarth2013]

Disability (ambulation, communication, swallowing)
Motor symptoms (dystonia, parkinsonism)
Non-motor symptoms (cognitive, behavioral)

Neuroimaging

MRI Findings

T2-weighted imaging:

Eye-of-the-tiger sign: Central hyperintensity surrounded by hypointensity in the globus pallidus (pathognomonic)
Hypointensity: Due to iron deposition in GPi and SNr
Hyperintensity: Central area of gliosis and cavitation

Other sequences:

T1: May show reduced signal in iron-affected regions
SWI/GRE: Sensitive to iron deposition
Diffusion: May show restricted diffusion in acute lesions

Imaging Evolution

Imaging changes typically precede clinical symptoms and progress over time:

Early: Subtle hypointensity in GP
Established: Eye-of-the-tiger sign
Advanced: Atrophy of GP and SN, involvement of other regions

Advanced Imaging

DTI: Shows decreased FA in affected regions
MRS: May show elevated lactate (mitochondrial dysfunction)
PET: Altered glucose metabolism in basal ganglia

Diagnosis

Diagnostic Criteria

Clinical diagnosis relies on:

Core features: Progressive movement disorder with iron accumulation on MRI

MRI findings: Eye-of-the-tiger sign

Genetic confirmation: Biallelic PANK2 mutations

Differential Diagnosis

Other NBIA subtypes must be considered:

PLAN (phospholipase A2, group VI): PLA2G6 mutations
FA2H: FA2H mutations
WDR45: WDR45 mutations (BPAN)
COASY: COASY mutations (CoA biosynthesis)
FHL1: FHL1 mutations
PKAN-like (PKANL): PANK2 mutations without typical MRI

Genetic Testing

Sequencing: PANK2 gene sequencing (full gene analysis)
Deletions/duplications: MLPA or similar methods
Carrier testing: For family members
Prenatal testing: Possible for at-risk pregnancies

Management

Current Therapeutic Approaches

Symptomatic Management:

Dystonia treatment:

Oral medications: Baclofen, benzodiazepines, anticholinergics (trihexyphenidyl)
Botulinum toxin injections for focal dystonia
Deep brain stimulation (DBS) of GPi

Parkinsonism treatment:

Dopaminergic agents (levodopa, dopamine agonists)
Variable response; often incomplete

Supportive care:

Physical therapy
Occupational therapy
Speech therapy
Nutritional support
Respiratory care

Disease-Modifying Therapies

CoA Antagonist Therapy (CoA-AS): [@klopstock2019]

The CoA-antagonist pantethine has been tested to reduce CoA synthesis (creating a "functional rescue" by reducing toxic intermediates):

Phase 2 trial showed some benefit in PKAN-RS scores
Currently under investigation in larger trials

Coenzyme A Supplementation:

Direct CoA administration is limited by blood-brain barrier penetration
Phosphopantethine (a CoA precursor) has been explored
Results have been mixed

Iron Chelation:

Deferoxamine has been tried with limited success
May slow iron accumulation but not reverse existing damage

Gene Therapy:

AAV-PANK2 delivery under investigation
Early-stage clinical trials planned

Deep Brain Stimulation

DBS of the internal segment of the globus pallidus (GPi-DBS) is an established treatment for severe dystonia in PKAN: [@bose2011]

Target: GPi (internal segment)
Outcomes: Significant reduction in dystonia scores
Benefits: Particularly effective for generalized dystonia
Limitations: Does not address underlying disease progression

Multi-Taxonomy Classification

Taxonomy Database Cross-References

| Taxonomy | ID | Name / Label |
|----------|-----|---------------|
| Cell Ontology (CL) | [CL:0000225](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000225) | globus pallidus neuron |
| Cell Ontology (CL) | [CL:0000540](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000540) | neuron |
| Cell Ontology (CL) | [CL:0000576](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000576) | GABAergic neuron |
| Uberon (UBERON) | [UBERON:0001906](https://www.ebi.ac.uk/ols4/ontologies/uberon/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FUBERON_0001906) | globus pallidus |

External Database Links

[Cell Ontology (CL:0000225)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000225)
[OBO Foundry (CL:0000225)](http://purl.obolibrary.org/obo/CL_0000225)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)

Animal Models

Available Models

Pank2 knockout mice: Show some metabolic abnormalities but limited neurodegeneration
Pank2 knockdown zebrafish: Model shows iron accumulation
Cell models: Patient-derived neurons and iPSC models

Research Applications

Understanding CoA metabolism in neurons
Testing therapeutic compounds
Gene therapy approaches

Future Directions

Gene therapy: AAV-mediated PANK2 delivery

CoA pathway modulators: Optimizing CoA-AS and CoA precursor approaches

Iron metabolism: Understanding iron accumulation and testing chelation

Biomarkers: Developing biomarkers for disease progression

Clinical trials: New therapeutic agents in clinical development

References

[Hayflick et al., PANK2 mutations in PKAN (2003)](https://doi.org/10.1212/01.WNL.0000059531.17754.7B)

[Gregory et al., Clinical features of NBIA (2009)](https://doi.org/10.1097/WCO.0b013e328328f0c8)

[Zhou et al., PANK2 mutations in Hallervorden-Spatz syndrome (2001)](https://doi.org/10.1038/ng718)

[Kell et al., Central role of CoA in human metabolism (2006)](https://doi.org/10.1016/j.mehy.2005.11.041)

[Leone et al., PKAN clinical management guidelines (2019)](https://doi.org/10.1016/j.ymgme.2019.02.009)

[Spiegel et al., Non-classical PKAN phenotypes (2006)](https://doi.org/10.1002/mds.21039)

[Arber et al., PANK2 and CoA metabolism (2020)](https://doi.org/10.1007/s12031-020-01552-5)

[Klopstock et al., CoA-antagonist therapy for PKAN (2019)](https://doi.org/10.1038/s41591-019-0358-8)

[Svetel et al., Dystonia in PKAN (2001)](https://doi.org/10.1002/mds.1173)

[Hogarth et al., PKAN rating scale (2013)](https://doi.org/10.1212/WNL.0b013e3182a8415a)

[Kristiansen et al., Genotype-phenotype in PKAN (2017)](https://doi.org/10.1093/brain/awx094)

[Zhang et al., Iron metabolism in PKAN (2015)](https://doi.org/10.1007/s12035-015-9301-0)

[Campolongo et al., CoA metabolism in PKAN (2012)](https://doi.org/10.1007/s10545-011-9407-4)

[Schneider et al., Natural history of PKAN (2016)](https://doi.org/10.1038/nrneurol.2015.225)

[Curtis et al., Ferritin mutations in NBIA (2002)](https://doi.org/10.1038/ng1049)

[Youdim & Riederer, Iron in brain and neurodegeneration (2000)](https://doi.org/10.1016/S0969-9961(00)00014-9)

[Post et al., Iron in Huntington's disease (1998)](https://doi.org/10.1097/00005072-199802000-00006)

[De \& Hayflick, Molecular basis of Hallervorden-Spatz (2002)](https://doi.org/10.1097/00008480-200212000-00005)

📖 View canonical wiki page →

Related Entities

cell-types-globus-pallidus-pkan

▸Metadataorigin_type: v1_polymorphic_backfill

slug	cell-types-globus-pallidus-pkan
kg_node_id	None
entity_type	cell_type
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-18ee519beee2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-globus-pallidus-pkan'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

26

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Globus Pallidus Pkan

Introduction

Overview

Introduction

Overview

PANK2 Gene and Protein

Gene Structure

Enzyme Function

Mutations

Coenzyme A Metabolism

Central Role of CoA

CoA Homeostasis in Neurons

Pathogenic Mechanisms of CoA Deficiency

Iron Metabolism in the Brain

Iron Homeostasis

Iron and Neurodegeneration

Why the Globus Pallidus?

Pathogenesis of PKAN

Primary Molecular Events

Secondary Pathogenic Mechanisms

Role of Iron Accumulation

Clinical Features

Classical (Early-Onset) PKAN

Atypical (Late-Onset) PKAN

Natural History

Rating Scales

Neuroimaging

MRI Findings

Imaging Evolution

Advanced Imaging

Diagnosis

Diagnostic Criteria

Differential Diagnosis

Genetic Testing

Management

Current Therapeutic Approaches

Disease-Modifying Therapies

Deep Brain Stimulation

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

Animal Models

Available Models

Research Applications

Future Directions

See Also

References

💬 Discussion